Download PDF
Horm Metab Res 2020; 52(06): 459-466
DOI: 10.1055/a-1120-8623
Review

Primary Aldosteronism: Where Are We Now? Where to from Here?

John Watson Funder
1   Hudson Institute of Medical Research and Monash University, Clayton, Victoria, Australia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The past nine years have seen major advances in establishing the etiology of unilateral primary aldosteronism, and very possibly that of bilateral hyperaldosteronism, in response to somatic mutations in aldosterone synthase expressing cells. Though there have been important advances in the management of primary aldosteronism, in small but convincing studies, they represent minor changes to current guidelines. What has been totally absent is consideration of the public health issue that primary aldosterone represents, and the public policy issues that would be involved in addressing the disorder. In his introduction to PiPA 6, Martin Reincke calculated that only one in a thousand patients in Germany with primary aldosteronism were treated appropriately, an astounding figure for any disease in the 21st century. Towards remedying this totally unacceptable public health issue, the author proposes a radical simplification and streamlining of screening for primary aldosteronism, and the management of most patients by general practitioners. The second bottle-neck in current management is that of mandatory adrenal venous sampling for all but 1–2% of patients, a costly procedure requiring rare expertise. Ideally, it should be reserved – on the basis of likelihood, enhanced imaging, or peripheral steroid profiles – for a small minority of patients with clear evidence for unilateral disease. Only when costs are minimized and roadblocks removed will primary aldosteronism be properly treated as the public health issue that it is.

Key words

somatic mutations - screening - lateralization - public health - health policy


Publication History

Received: 20 November 2019

Accepted: 10 February 2020

Article published online:
04 May 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Choi M, Scholl UI, Yue P. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
    CrossrefPubMedGoogle Scholar
  • 2 Boulkroun S, Beuschlein F, Rossi GP. et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59: 592-598
    CrossrefPubMedGoogle Scholar
  • 3 Azizan EA, Murthy M, Stowasser M. et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59: 587-591
    CrossrefPubMedGoogle Scholar
  • 4 Azizan EA, Lam BY, Newhouse SJ. et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 2012; 97: E819-E829
    CrossrefPubMedGoogle Scholar
  • 5 Monticone S, Hattangady NG, Nishimoto K. et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 2012; 97: E1567-E1572
    CrossrefPubMedGoogle Scholar
  • 6 Åkerström T, Crona J, Delgado Verdugo A. et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 2012; 7: e41926
    CrossrefPubMedGoogle Scholar
  • 7 Geller DS, Zhang J, Wisgerhof MV. et al. A novel form of human mendelian hypertension featuring nonglucocorticoidremediable aldosteronism. J Clin Endocrinol Metab 2008; 93: 3117-3123
    CrossrefPubMedGoogle Scholar
  • 8 Stowasser M, Gordon RD, Tunny TJ. et al. Familial hyperaldosteronism type II: Five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992; 19: 319-322
    CrossrefPubMedGoogle Scholar
  • 9 Taguchi R, Yamada M, Nakajima Y. et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone producing adenomas. J Clin Endocrinol Metab 2012; 97: 1311-1319
    CrossrefPubMedGoogle Scholar
  • 10 Zheng FF, Zhu LM, Nie AF. et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone producing adenoma. Hypertension 2015; 65: 622-628
    CrossrefPubMedGoogle Scholar
  • 11 Scholl UI, Goh G, Stölting G. et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45: 1050-1054
    CrossrefPubMedGoogle Scholar
  • 12 Scholl UI, Stölting G, Nelson-Williams C. et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 2015; 4: e06315
    CrossrefPubMedGoogle Scholar
  • 13 Azizan EA, Poulsen H, Tuluc P. et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45: 1055-1060
    CrossrefPubMedGoogle Scholar
  • 14 Beuschlein F, Boulkroun S, Osswald A. et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45: 440-444
    CrossrefPubMedGoogle Scholar
  • 15 Åkerström T, Maharjan R, Sven Willenberg H. et al. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci Rep 2016; 6: 19546
    CrossrefPubMedGoogle Scholar
  • 16 Scholl UI, Stölting G, Schewe J. et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet 2018; 50: 349-354
    CrossrefPubMedGoogle Scholar
  • 17 Fernandes-Rosa FL, Daniil G, Orozco IJ. et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet 2018; 50: 355-361
    CrossrefPubMedGoogle Scholar
  • 18 Nanba K, Blinder AR, Rege J. et al. Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma. Hypertension 2020; 75: 645-649
    CrossrefPubMedGoogle Scholar
  • 19 Nanba K, Omata K, Else T. et al. Targeted molecular characterization of aldosterone-producing adenomas in white Americans. J Clin Endocrinol Metab 2018; 103: 3869-3876
    CrossrefPubMedGoogle Scholar
  • 20 Nanba K, Omata K, Gomez-Sanchez CE. et al. Genetic Characteristics of aldosterone-producing adenomas in blacks. Hypertension 2019; 73: 885-892
    CrossrefPubMedGoogle Scholar
  • 21 Nishimoto K, Tomlins SA, Kuick R. et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA 2015; 112: E4591-E4599
    CrossrefPubMedGoogle Scholar
  • 22 Omata K, Anand SK, Hovelson DH. et al. Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals. J Endocr Soc 2017; 1: 787-799
    CrossrefPubMedGoogle Scholar
  • 23 Omata K, Satoh F, Morimoto R. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018; 72: 874-880
    CrossrefPubMedGoogle Scholar
  • 24 Ahmed AH, Cowley D, Wolley M. et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: A preliminary study. J Clin Endocrinol Metab 2014; 99: 2745-2753
    CrossrefPubMedGoogle Scholar
  • 25 Stowasser M, Ahmed AH, Cowley D. et al. Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2018; 103: 4113-4124
    CrossrefPubMedGoogle Scholar
  • 26 Gouli A, Kaltsas G, Tzonou A. et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011; 41: 1227-1236
    CrossrefPubMedGoogle Scholar
  • 27 Markou A, Sertedaki A, Kaltsas G. et al. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab 2015; 100: 2857-2864
    CrossrefPubMedGoogle Scholar
  • 28 Helber A, Wambach G, Hummerich W. et al. Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. Klin Wochenschr 1980; 58: 439-447
    CrossrefPubMedGoogle Scholar
  • 29 Baudrand R, Guarda FJ, Fardella C. et al. Continuum of renin-independent aldosteronism in normotension. Hypertension 2017; 69: 950-956
    CrossrefPubMedGoogle Scholar
  • 30 Stowasser M, Sharman J, Leano R. et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90: 5070-5076
    Google Scholar
  • 31 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-59
    CrossrefPubMedGoogle Scholar
  • 32 Milliez P, Girerd X, Plouin PF. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
    CrossrefPubMedGoogle Scholar
  • 33 Savard S, Amar L, Plouin PF. et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62: 331-336
    CrossrefPubMedGoogle Scholar
  • 34 Monticone S, D'Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50
    CrossrefPubMedGoogle Scholar
  • 35 Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e15985
    CrossrefPubMedGoogle Scholar
  • 36 Rakugi H, Ito S, Itoh H. et al. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res 2019; 42: 1932-1941
    CrossrefPubMedGoogle Scholar
  • 37 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection diagnosis and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
    CrossrefPubMedGoogle Scholar
  • 38 Burton TJ, Mackenzie IS, Balan K. et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab 2012; 97: 100-109
    CrossrefPubMedGoogle Scholar
  • 39 Abe T, Naruse M, Young WF. et al. A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism. J Clin Endocrinol Metab 2016; 101: 1008-1015
    CrossrefPubMedGoogle Scholar
  • 40 Satoh F, Morimoto R, Ono Y. et al. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension 2015; 65: 1096-1102
    CrossrefPubMedGoogle Scholar
  • 41 Nishikawa T, Omura M, Satoh F. et al. Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J 2011; 58: 711-721
    CrossrefPubMedGoogle Scholar
  • 42 Mulatero P, Monticone S, Burrello J. et al. Guidelines for primary aldosteronism: Uptake by primary care physicians in Europe. J Hypertens 2016; 34: 2253-2257
    CrossrefPubMedGoogle Scholar
  • 43 Funder JW. Primary Aldosteronism. Hypertension 2019; 74: 458-466
    CrossrefPubMedGoogle Scholar
  • 44 Dostanic-Larson I, Vay Huysse JW, Lorenz JN. et al. The highly conserved cardiac glycoside binding site of Na,K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci U S A 2005; 102: 15845-15850
    CrossrefPubMedGoogle Scholar